Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer

Fast and accurate short read alignment with Burrows-Wheeler transform

Li, H., & Durbin, R. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp324 · Cited by 58,607

PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer

Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989

Ultrafast and memory-efficient alignment of short DNA sequences to the human genome.

Langmead, B., Trapnell, C., Pop, M., & Salzberg, S. L. (2009) · Genome Biology · doi:10.1186/gb-2009-10-3-r25 · Cited by 21,849

Mapping and quantifying mammalian transcriptomes by RNA-Seq

Mortazavi, A., Williams, B. A., McCue, K., Schaeffer, L., & Wold, B. (2008) · Nature Methods · doi:10.1038/nmeth.1226 · Cited by 13,696

Primer3—new capabilities and interfaces

Untergasser, A., Cutcutache, I., Kõressaar, T., Ye, J., Faircloth, B., Remm, M., & Rozen, S. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks596 · Cited by 9,165

Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration

Thorvaldsdottir, H., Robinson, J. T., & Mesirov, J. P. (2013) · Briefings in Bioinformatics · doi:10.1093/bib/bbs017 · Cited by 9,049

<tt>BLAT</tt> —The <tt>BLAST</tt> -Like Alignment Tool

Kent, W. J. (2002) · Genome Research · doi:10.1101/gr.229202 · Cited by 8,480

Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer

Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802

PD-1 blockade induces responses by inhibiting adaptive immune resistance

Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609

Pembrolizumab versus Ipilimumab in Advanced Melanoma

Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887

The perfect personalized cancer therapy: cancer vaccines against neoantigens

Aurisicchio, L., Pallocca, M., Ciliberto, G., & Palombo, F. (2018) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-0751-1 · Cited by 93

Modularly Programmable Nanoparticle Vaccine Based on Polyethyleneimine for Personalized Cancer Immunotherapy

Nam, J., Son, S., Park, K. S., & Moon, J. J. (2021) · Advanced Science · doi:10.1002/advs.202002577 · Cited by 92

The MHC Motif Atlas: a database of MHC binding specificities and ligands

Tadros, D. M., Eggenschwiler, S., Racle, J., & Gfeller, D. (2022) · Nucleic Acids Research · doi:10.1093/nar/gkac965 · Cited by 90

‘Hotspots’ of Antigen Presentation Revealed by Human Leukocyte Antigen Ligandomics for Neoantigen Prioritization

Müller, M., Gfeller, D., Coukos, G., & Bassani‐Sternberg, M. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01367 · Cited by 87

Glycan-Modified Apoptotic Melanoma-Derived Extracellular Vesicles as Antigen Source for Anti-Tumor Vaccination

Horrevorts, S. K., Stolk, D. A., van de Ven, R., Hulst, M., Hof, B. V. H., Duinkerken, S., Heineke, M. H., Ma, W., Dusoswa, S. A., Nieuwland, R., et al. (2019) · Cancers · doi:10.3390/cancers11091266 · Cited by 91

Endogenous CD4+ T Cells Recognize Neoantigens in Lung Cancer Patients, Including Recurrent Oncogenic KRAS and ERBB2 ( Her2 ) Driver Mutations

Veatch, J. R., Jesernig, B. L., Kargl, J., Fitzgibbon, M., Lee, S. M., Baik, C., Martins, R., Houghton, A. M., & Riddell, S. R. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0402 · Cited by 89

Hybrid Biopolymer and Lipid Nanoparticles with Improved Transfection Efficacy for mRNA

Siewert, C. D., Haas, H., Cornet, V., Nogueira, S. S., Nawroth, T., Uebbing, L., Ziller, A., Al-Gousous, J., Rădulescu, A., Schroer, M. A., et al. (2020) · Cells · doi:10.3390/cells9092034 · Cited by 92

HNSCC: Tumour Antigens and Their Targeting by Immunotherapy

Witzleben, A. V., Wang, C., Laban, S. A., Savelyeva, N., & Ottensmeier, C. H. H. (2020) · Cells · doi:10.3390/cells9092103 · Cited by 93

A machine learning model for ranking candidate HLA class I neoantigens based on known neoepitopes from multiple human tumor types

Gartner, J. J., Parkhurst, M. R., Gros, A., Tran, E., Jafferji, M. S., Copeland, A. R., Hanada, K., Zacharakis, N., Lalani, A., Krishna, S., et al. (2021) · Nature Cancer · doi:10.1038/s43018-021-00197-6 · Cited by 90

Immune evasion of dormant disseminated tumor cells is due to their scarcity and can be overcome by T cell immunotherapies

Goddard, E. T., Linde, M. H., Srivastava, S., Klug, G., Shabaneh, T. B., Iannone, S., Grzelak, C. A., Marsh, S. A., Riggio, A. I., Shor, R. E., et al. (2024) · Cancer Cell · doi:10.1016/j.ccell.2023.12.011 · Cited by 96

Neoantigen DNA vaccines are safe, feasible, and induce neoantigen-specific immune responses in triple-negative breast cancer patients

Zhang, X., Goedegebuure, S. P., Chen, M. Y., Mishra, R., Zhang, F., Yu, Y. Y., Singhal, K., Li, L., Gao, F., Myers, N. B., et al. (2024) · Genome Medicine · doi:10.1186/s13073-024-01388-3 · Cited by 89

Tumour and microenvironment crosstalk in NSCLC progression and response to therapy

Rahal, Z., Darzi, R. E., Moghaddam, S. J., Cascone, T., & Kadara, H. N. (2025) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-025-01021-1 · Cited by 105

Hijacked Immune Cells in the Tumor Microenvironment: Molecular Mechanisms of Immunosuppression and Cues to Improve T Cell-Based Immunotherapy of Solid Tumors

Balta, E., Wabnitz, G. H., & Samstag, Y. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115736 · Cited by 88

Nucleic Acid Drugs—Current Status, Issues, and Expectations for Exosomes

Yamada, Y. (2021) · Cancers · doi:10.3390/cancers13195002 · Cited by 92

Dynamic Cancer Cell Heterogeneity: Diagnostic and Therapeutic Implications

Jacquemin, V., Antoine, M., Dom, G., Detours, V., Maenhaut, C., & Dumont, J. E. (2022) · Cancers · doi:10.3390/cancers14020280 · Cited by 92

Precision medicine in diabetes: an opportunity for clinical translation

Merino, J., & Florez, J. C. (2018) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.13588 · Cited by 90

Self-adjuvanting nanoemulsion targeting dendritic cell receptor Clec9A enables antigen-specific immunotherapy

Zeng, B., Middelberg, A. P. J., Gemiarto, A. T., MacDonald, K. P. A., Baxter, A. G., Talekar, M., Moi, D., Tullett, K. M., Caminschi, I., Lahoud, M. H., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci96791 · Cited by 87

mRNA nanodelivery systems: targeting strategies and administration routes

Yuan, M., Han, Z., Liang, Y., Sun, Y., He, B., Chen, W., & Fan, L. (2023) · Biomaterials Research · doi:10.1186/s40824-023-00425-3 · Cited by 98

Recent progress in mRNA cancer vaccines

Yao, R., Xie, C., & Xia, X. (2024) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2024.2307187 · Cited by 91

Small circular RNAs as vaccines for cancer immunotherapy

Zhang, Y., Liu, X., Shen, T., Wang, Q., Zhou, S., Yang, S., Liao, S., Su, T., Mei, L., Zhang, B., et al. (2025) · Nature Biomedical Engineering · doi:10.1038/s41551-025-01344-5 · Cited by 94

Poly(propylacrylic acid)-peptide nanoplexes as a platform for enhancing the immunogenicity of neoantigen cancer vaccines

Qiu, F. X., Becker, K. W., Knight, F. C., Baljon, J. J., Sevimli, S., Shae, D., Gilchuk, P., Joyce, S., & Wilson, J. T. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2018.07.052 · Cited by 87

The current clinical landscape of personalized cancer vaccines

Fritah, H., Rovelli, R., Chiang, C. L.-L., & Kandalaft, L. E. (2022) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2022.102383 · Cited by 87

The T-cell-directed vaccine BNT162b4 encoding conserved non-spike antigens protects animals from severe SARS-CoV-2 infection

Arieta, C. M., Xie, Y. J., Rothenberg, D., Diao, H., Harjanto, D., Meda, S., Marquart, K., Koenitzer, B., Sciuto, T. E., Lobo, A., et al. (2023) · Cell · doi:10.1016/j.cell.2023.04.007 · Cited by 88

Vaccination-induced skin-resident memory CD8 + T cells mediate strong protection against cutaneous melanoma

Gálvez‐Cancino, F., López, E., Menares, E., Díaz, X., Flores, C., Cáceres, P., Hidalgo, S., Chovar, O., Alcántara‐Hernández, M., Borgna, V., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1442163 · Cited by 91

Systems Immunology: Learning the Rules of the Immune System

Villani, A., Sarkizova, S., & Hacohen, N. (2018) · Annual Review of Immunology · doi:10.1146/annurev-immunol-042617-053035 · Cited by 89

Efficient identification of neoantigen-specific T-cell responses in advanced human ovarian cancer

Liu, S., Matsuzaki, J., Wei, L., Tsuji, T., Battaglia, S., Hu, Q., Cortes, E., Wong, L.-P., Yan, L., Long, M. D., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0629-6 · Cited by 85

Antibody-mediated delivery of viral epitopes to tumors harnesses CMV-specific T cells for cancer therapy

Millar, D. G., Ramjiawan, R. R., Kawaguchi, K., Gupta, N., Jiang, C., Zhang, S., Nojiri, T., Ho, W. W., Aoki, S., Jung, K., et al. (2020) · Nature Biotechnology · doi:10.1038/s41587-019-0404-8 · Cited by 85

MHC-restricted phosphopeptide antigens: preclinical validation and first-in-humans clinical trial in participants with high-risk melanoma

Engelhard, V. H., Obeng, R. C., Cummings, K. L., Petroni, G. R., Ambakhutwala, A. L., Chianese‐Bullock, K. A., Smith, K. T., Lulu, A. M., Varhegyi, N., Smolkin, M. E., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000262 · Cited by 87

Cancer Vaccines: Antigen Selection Strategy

Zhao, Y., Baldin, A. V., Isayev, O., Werner, J., Zamyatnin, A. A., & Bazhin, A. V. (2021) · Vaccines · doi:10.3390/vaccines9020085 · Cited by 87

Personalized cancer vaccine design using AI-powered technologies

Kumar, A., Dixit, S., Srinivasan, K., Dinakaran, M., & Vincent, P. M. D. R. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1357217 · Cited by 94

Enhancement of Peptide Vaccine Immunogenicity by Increasing Lymphatic Drainage and Boosting Serum Stability

Moynihan, K. D., Holden, R. L., Mehta, N. K., Wang, C., Karver, M. R., Dinter, J., Liang, S., Abraham, W. D., Melo, M. B., Zhang, A. Q., et al. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0607 · Cited by 81

Therapeutic cancer vaccine: building the future from lessons of the past

Tran, T., Blanc, C., Granier, C., Saldmann, A., Tanchot, C., & Tartour, É. (2018) · Seminars in Immunopathology · doi:10.1007/s00281-018-0691-z · Cited by 85

Acute myeloid leukemia cell membrane-coated nanoparticles for cancer vaccination immunotherapy

Johnson, D. T., Zhou, J., Kroll, A. V., Fang, R. H., Yan, M., Xiao, C., Chen, X., Kline, J. P., Zhang, L., & Zhang, D. (2021) · Leukemia · doi:10.1038/s41375-021-01432-w · Cited by 87

Recent progress of dendritic cell-derived exosomes (Dex) as an anti-cancer nanovaccine

Xia, J., Miao, Y., Wang, X., Huang, X., & Dai, J. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113250 · Cited by 89

Metal‐Organic Frameworks for Gene Therapy and Detection

He, Y., Li, D., Wu, L., Yin, X., Zhang, X., Patterson, L. H., & Zhang, J. (2023) · Advanced Functional Materials · doi:10.1002/adfm.202212277 · Cited by 85

The 2018 Nobel Prize in medicine goes to cancer immunotherapy

Guo, Z. S. (2018) · BMC Cancer · doi:10.1186/s12885-018-5020-3 · Cited by 88

Testing thousands of nanoparticles in vivo using DNA barcodes

Lokugamage, M. P., Sago, C. D., & Dahlman, J. E. (2018) · Current Opinion in Biomedical Engineering · doi:10.1016/j.cobme.2018.08.001 · Cited by 84

Deciphering CD4+ T cell specificity using novel MHC–TCR chimeric receptors

Kisielow, J., Obermair, F.-J., & Köpf, M. (2019) · Nature Immunology · doi:10.1038/s41590-019-0335-z · Cited by 83

Vaccines for immunoprevention of cancer

Enokida, T., Moreira, A., & Bhardwaj, N. (2021) · Journal of Clinical Investigation · doi:10.1172/jci146956 · Cited by 85

Personalized neoantigen vaccine combined with PD-1 blockade increases CD8+ tissue-resident memory T-cell infiltration in preclinical hepatocellular carcinoma models

Chen, H., Li, Z., Qiu, L., Dong, X., Chen, G., Shi, Y., Cai, L., Liu, W., Ye, H., Zhou, Y., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-004389 · Cited by 85

Vaccines as treatments for prostate cancer

Rastogi, I., Muralidhar, A., & McNeel, D. G. (2023) · Nature Reviews Urology · doi:10.1038/s41585-023-00739-w · Cited by 86

Eliciting antitumor immunity via therapeutic cancer vaccines

Peng, K., Zhao, X., Fu, Y., & Liang, Y. (2025) · Cellular and Molecular Immunology · doi:10.1038/s41423-025-01316-4 · Cited by 104

Steatohepatitis Impairs T-cell–Directed Immunotherapies Against Liver Tumors in Mice

Heinrich, B., Brown, Z. J., Diggs, L. P., Vormehr, M., Ma, C., Subramanyam, V., Rosato, U., Ruf, B., Walz, J. S., McVey, J. C., et al. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.09.031 · Cited by 81

Performance Evaluation of MHC Class-I Binding Prediction Tools Based on an Experimentally Validated MHC–Peptide Binding Data Set

Bonsack, M., Hoppe, S., Winter, J., Tichy, D., Zeller, C. M., Kupper, M. D., Schitter, E. C., Blatnik, R., & Riemer, A. B. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0584 · Cited by 83

Safety and Efficacy of Therapeutic Cancer Vaccines Alone or in Combination With Immune Checkpoint Inhibitors in Cancer Treatment

Zhao, J., Chen, Y., Ding, Z., & Liu, J. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01184 · Cited by 80

Treatment of an aggressive orthotopic murine glioblastoma model with combination checkpoint blockade and a multivalent neoantigen vaccine

Liu, C. J., Schaettler, M. O., Blaha, D. T., Bowman-Kirigin, J. A., Kobayashi, D. K., Livingstone, A. J., Bender, D. E., Miller, C. A., Kranz, D. M., Johanns, T. M., et al. (2020) · Neuro-Oncology · doi:10.1093/neuonc/noaa050 · Cited by 86

Architects of immunity: How dendritic cells shape CD8 + T cell fate in cancer

Bhandarkar, V., Dinter, T., & Spranger, S. (2025) · Science Immunology · doi:10.1126/sciimmunol.adf4726 · Cited by 88

mRNA in cancer immunotherapy: beyond a source of antigen

Hoecke, L. V., Verbeke, R., Dewitte, H., Lentacker, I., Vermaelen, K. Y., Breckpot, K., & Lint, S. V. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01329-3 · Cited by 85

Combination Neoantigen-Based Dendritic Cell Vaccination and Adoptive T-Cell Transfer Induces Antitumor Responses Against Recurrence of Hepatocellular Carcinoma

Peng, S., Chen, S., Hu, W., Mei, J., Zeng, X., Su, T., Wang, W., Chen, Z., Xiao, H., Zhou, Q., et al. (2022) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-21-0931 · Cited by 79

Immune-based combination therapy to convert immunologically cold tumors into hot tumors: an update and new insights

Ni, J., Zhang, Z., Ge, M.-J., Chen, J., & Zhuo, W. (2022) · Acta Pharmacologica Sinica · doi:10.1038/s41401-022-00953-z · Cited by 85

Development of therapeutic vaccines for the treatment of diseases

Tian, Y., Hu, D., Li, Y., & Li, Y. (2022) · Molecular Biomedicine · doi:10.1186/s43556-022-00098-9 · Cited by 89

mRNA vaccine with unmodified uridine induces robust type I interferon-dependent anti-tumor immunity in a melanoma model

Sittplangkoon, C., Alameh, M.-G., Weissman, D., Lin, P. J. C., Tam, Y. K., Prompetchara, E., & Palaga, T. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.983000 · Cited by 79

COVID-19 in Human, Animal, and Environment: A Review

Swelum, A. A., Shafi, M. E., Albaqami, N. M., El‐Saadony, M. T., Elsify, A. M., Abdo, M., Taha, A. E.-S., Abdel‐Moneim, A. E., Al-Gabri, N. A., Almaiman, A. A., et al. (2020) · Frontiers in Veterinary Science · doi:10.3389/fvets.2020.00578 · Cited by 83

Maximizing the Translational Yield of mRNA Therapeutics by Minimizing 5′-UTRs

Trepotec, Z., Aneja, M. K., Geiger, J., Hasenpusch, G., Plank, C., & Rudolph, C. (2019) · Tissue Engineering Part A · doi:10.1089/ten.tea.2017.0485 · Cited by 77

Polymer-lipid hybrid nanovesicle-enabled combination of immunogenic chemotherapy and RNAi-mediated PD-L1 knockdown elicits antitumor immunity against melanoma

Wang, C., Shi, X., Song, H., Zhang, C., Wang, X., Huang, P., Dong, A., Zhang, Y., Kong, D., & Wang, W. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2020.120579 · Cited by 77

Targeting neoantigens for cancer immunotherapy

Zhao, X., Pan, X., Wang, Y., & Zhang, Y. (2021) · Biomarker Research · doi:10.1186/s40364-021-00315-7 · Cited by 78

Cancer Neoantigens: Challenges and Future Directions for Prediction, Prioritization, and Validation

Borden, E. S., Buetow, K. H., Wilson, M. A., & Hastings, K. T. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.836821 · Cited by 86

The oncogenic fusion protein DNAJB1-PRKACA can be specifically targeted by peptide-based immunotherapy in fibrolamellar hepatocellular carcinoma

Bauer, J., Köhler, N., Maringer, Y., Bucher, P., Bilich, T., Zwick, M., Dicks, S., Nelde, A., Dubbelaar, M. L., Scheid, J., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-33746-3 · Cited by 77

Antigen cross-presentation by dendritic cells: A critical axis in cancer immunotherapy

Moussion, C., & Delamarre, L. (2023) · Seminars in Immunology · doi:10.1016/j.smim.2023.101848 · Cited by 82

Mutational landscape of the transcriptome offers putative targets for immunotherapy of myeloproliferative neoplasms

Schischlik, F., Jäger, R., Rosebrock, F., Hug, E., Schuster, M. K., Holly, R., Fuchs, E., Feenstra, J. D. M., Bogner, E., Gisslinger, B., et al. (2019) · Blood · doi:10.1182/blood.2019000519 · Cited by 77

Direct Detection and Quantification of Neoantigens

Wang, Q., Douglass, J., Hwang, M. S., Hsiue, E. H.-C., Mog, B. J., Zhang, M., Papadopoulos, N., Kinzler, K. W., Zhou, S., & Vogelstein, B. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0107 · Cited by 81

Therapeutic Cancer Vaccination with Ex Vivo RNA-Transfected Dendritic Cells—An Update

Dörrie, J., Schaft, N., Schuler, G., & Schuler‐Thurner, B. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12020092 · Cited by 79

Uncovering the Tumor Antigen Landscape: What to Know about the Discovery Process

Feola, S., Chiaro, J., Martins, B., & Cerullo, V. (2020) · Cancers · doi:10.3390/cancers12061660 · Cited by 86

Combining Cancer Vaccines with Immunotherapy: Establishing a New Immunological Approach

Kim, C.-G., Sang, Y. B., Lee, J. H., & Chon, H. J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22158035 · Cited by 78

A Neoantigen-Based Peptide Vaccine for Patients With Advanced Pancreatic Cancer Refractory to Standard Treatment

Chen, Z., Zhang, S., Han, N., Jiang, J., Xu, Y., Ma, D., Lu, L., Guo, X., Qiu, M. R., Huang, Q., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.691605 · Cited by 79

mRNA Cancer Vaccines: Construction and Boosting Strategies

Liu, X., Huang, P., Yang, R., & Deng, H. (2023) · ACS Nano · doi:10.1021/acsnano.3c05635 · Cited by 79

Multi-Omics Profiling of the Tumor Microenvironment: Paving the Way to Precision Immuno-Oncology

Finotello, F., & Eduati, F. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00430 · Cited by 77

Evolution of Cancer Vaccines—Challenges, Achievements, and Future Directions

Tay, B. Q., Wright, Q., Ladwa, R., Perry, C., Leggatt, G., Simpson, F., Wells, J. W., Panizza, B. J., Frazer, I. H., & Cruz, J. L. G. (2021) · Vaccines · doi:10.3390/vaccines9050535 · Cited by 76

Immune Regulation by Dendritic Cell Extracellular Vesicles in Cancer Immunotherapy and Vaccines

Fernández‐Delgado, I., Calzada‐Fraile, D., & Sánchez‐Madrid, F. (2020) · Cancers · doi:10.3390/cancers12123558 · Cited by 79

Therapeutic strategies to remodel immunologically cold tumors

Wang, M., Wang, S., Desai, J., Trapani, J. A., & Neeson, P. J. (2020) · Clinical & Translational Immunology · doi:10.1002/cti2.1226 · Cited by 79

Structural dissimilarity from self drives neoepitope escape from immune tolerance

Devlin, J. R., Alonso, J. A., Ayres, C. M., Keller, G. L. J., Bobisse, S., Kooi, C. W. V., Coukos, G., Gfeller, D., Harari, A., & Baker, B. M. (2020) · Nature Chemical Biology · doi:10.1038/s41589-020-0610-1 · Cited by 70

A Phase Ib Study of the Combination of Personalized Autologous Dendritic Cell Vaccine, Aspirin, and Standard of Care Adjuvant Chemotherapy Followed by Nivolumab for Resected Pancreatic Adenocarcinoma—A Proof of Antigen Discovery Feasibility in Three Patients

Bassani‐Sternberg, M., Digklia, A., Huber, F., Wagner, D., Sempoux, C. L., Stevenson, B. J., Thierry, A., Michaux, J., Pak, H., Racle, J., et al. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01832 · Cited by 75

Prognostic impact of CD4-positive T cell subsets in early breast cancer: a study based on the FinHer trial patient population

Schmidt, M., Weyer‐Elberich, V., Hengstler, J. G., Heimes, A.-S., Almstedt, K., Gerhold‐Ay, A., Lebrecht, A., Battista, M. J., Hasenburg, A., Şahin, U., et al. (2018) · Breast Cancer Research · doi:10.1186/s13058-018-0942-x · Cited by 78

Nanocarriers for cancer nano-immunotherapy

Rana, I., Oh, J., Baig, J., Moon, J. H., Son, S., & Nam, J. (2022) · Drug Delivery and Translational Research · doi:10.1007/s13346-022-01241-3 · Cited by 76

Correlates of immune and clinical activity of novel cancer vaccines

van der Burg, S. H. (2018) · Seminars in Immunology · doi:10.1016/j.smim.2018.04.001 · Cited by 76

Detection of neoantigen-specific T cells following a personalized vaccine in a patient with glioblastoma

Johanns, T. M., Miller, C. A., Liu, C. J., Perrin, R. J., Bender, D. E., Kobayashi, D. K., Campian, J. L., Chicoine, M. R., Dacey, R. G., Huang, J., et al. (2019) · OncoImmunology · doi:10.1080/2162402x.2018.1561106 · Cited by 75

Computational Pipeline for the PGV-001 Neoantigen Vaccine Trial

Rubinsteyn, A., Kodysh, J., Hodes, I., Mondet, S., Aksoy, B. A., Finnigan, J. P., Bhardwaj, N., & Hammerbacher, J. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01807 · Cited by 74

An innovative plasmacytoid dendritic cell line-based cancer vaccine primes and expands antitumor T-cells in melanoma patients in a first-in-human trial

Charles, J., Chaperot, L., Hannani, D., Costa, J. B., Templier, I., Trabelsi, S., Gil, H., Moisan, A., Persoons, V., Hegelhofer, H., et al. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1738812 · Cited by 75

Cell and tissue engineering in lymph nodes for cancer immunotherapy

Najibi, A. J., & Mooney, D. J. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.07.023 · Cited by 73

Cancer Vaccines: Promising Therapeutics or an Unattainable Dream

Donninger, H., Li, C., Eaton, J. W., & Yaddanapudi, K. (2021) · Vaccines · doi:10.3390/vaccines9060668 · Cited by 74

Neoantigen vaccination induces clinical and immunologic responses in non-small cell lung cancer patients harboring EGFR mutations

Li, F., Deng, L., Jackson, K. R., Talukder, A. H., Katailiha, A. S., Bradley, S. D., Zou, Q., Chen, C., Huo, C., Chiu, Y., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002531 · Cited by 74

Recent Advances and Next Breakthrough in Immunotherapy for Cancer Treatment

Yang, L., Ning, Q., & Tang, S. (2022) · Journal of Immunology Research · doi:10.1155/2022/8052212 · Cited by 78

Synergistic potential of immune checkpoint inhibitors and therapeutic cancer vaccines

Oladejo, M., Paulishak, W., & Wood, L. M. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.12.003 · Cited by 75

Nucleic Acid-Based Approaches for Tumor Therapy

Hager, S., Fittler, F. J., Wagner, E., & Bros, M. (2020) · Cells · doi:10.3390/cells9092061 · Cited by 78

Hepatocellular Carcinoma Growth Retardation and PD-1 Blockade Therapy Potentiation with Synthetic High-density Lipoprotein

Wang, J., Meng, J., Wei, R., Lee, R. J., Teng, L., Zhang, P., & Li, Y. (2019) · Nano Letters · doi:10.1021/acs.nanolett.9b01717 · Cited by 72

Injectable Supramolecular Hydrogel for Locoregional Immune Checkpoint Blockade and Enhanced Cancer Chemo-Immunotherapy

Liu, M., Cao, Z., Zhang, R., Chen, Y., & Yang, X. (2021) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.1c08285 · Cited by 71

Cancer vaccines: past, present and future; a review article

Grimmett, E., Al-Share, B. A., Alkassab, M. B., Zhou, R. W., Desai, A., Rahim, M. M. A., & Woldie, I. (2022) · Discover Oncology · doi:10.1007/s12672-022-00491-4 · Cited by 77

The future of cancer immunotherapy: DNA vaccines leading the way

Pandya, A. J., Shah, Y. B., Kothari, N. R., Postwala, H. I., Shah, A. C., Parekh, P. S., & Chorawala, M. R. (2023) · Medical Oncology · doi:10.1007/s12032-023-02060-3 · Cited by 80

Tumor Vaccines: Unleashing the Power of the Immune System to Fight Cancer

Liu, D., Che, X., Wang, X., Ma, C., & Wu, G. (2023) · Pharmaceuticals · doi:10.3390/ph16101384 · Cited by 84

Nanotechnology‐Assisted RNA Delivery: From Nucleic Acid Therapeutics to COVID‐19 Vaccines

Rinoldi, C., Zargarian, S. S., Nakielski, P., Li, X., Liguori, A., Petronella, F., Presutti, D., Wang, Q., Costantini, M., Sio, L. D., et al. (2021) · Small Methods · doi:10.1002/smtd.202100402 · Cited by 78

Enhancing therapeutic performance of personalized cancer vaccine via delivery vectors

Ye, T., Li, F., Ma, G., & Wei, W. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.113927 · Cited by 73

Computational immunogenomic approaches to predict response to cancer immunotherapies

Addala, V., Newell, F., Pearson, J. V., Redwood, A., Robinson, B. W. S., Creaney, J., & Waddell, N. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00830-6 · Cited by 79

Long-lasting mRNA-encoded interleukin-2 restores CD8+ T cell neoantigen immunity in MHC class I-deficient cancers

Beck, J. D., Diken, M., Suchan, M., Streuber, M., Diken, E., KOLB, L. D., Allnoch, L., Vascotto, F., Peters, D., Beißert, T., et al. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.02.013 · Cited by 72

dbPepNeo: a manually curated database for human tumor neoantigen peptides

Tan, X., Li, D., Huang, P., Jian, X., Wan, H., Wang, G., Li, Y., Ouyang, J., Lin, Y., & Xie, L. (2020) · Database · doi:10.1093/database/baaa004 · Cited by 71

Systemically Administered TLR7/8 Agonist and Antigen-Conjugated Nanogels Govern Immune Responses against Tumors

Stickdorn, J., Stein, L., Arnold-Schild, D., Hahlbrock, J., Medina‐Montano, C., Bartneck, J., Ziß, T., Montermann, E., Kappel, C., Hobernik, D., et al. (2022) · ACS Nano · doi:10.1021/acsnano.1c10709 · Cited by 70

Mucosal immunity and vaccination strategies: current insights and future perspectives

Zhang, Z., Hong, W., Zhang, Y., Li, X., Que, H., & Wei, X. (2025) · Molecular Biomedicine · doi:10.1186/s43556-025-00301-7 · Cited by 81

Investigation of pH-Responsiveness inside Lipid Nanoparticles for Parenteral mRNA Application Using Small-Angle X-ray Scattering

Uebbing, L., Ziller, A., Siewert, C., Schroer, M. A., Blanchet, C. E., Svergun, D. I., Ramishetti, S., Peer, D., Şahin, U., Haas, H., et al. (2020) · Langmuir · doi:10.1021/acs.langmuir.0c02446 · Cited by 68

Targeting the Tumor Microenvironment for Improving Therapeutic Effectiveness in Cancer Immunotherapy: Focusing on Immune Checkpoint Inhibitors and Combination Therapies

Chyuan, I., Chu, C., & Hsu, P. (2021) · Cancers · doi:10.3390/cancers13061188 · Cited by 68

Cancer/testis antigens: from serology to mRNA cancer vaccine

Fan, C., Qu, H., Wang, X., Sobhani, N., Wang, L., Liu, S., Xiong, W., Zeng, Z., & Li, Y. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.04.016 · Cited by 72

Linked CD4+/CD8+ T cell neoantigen vaccination overcomes immune checkpoint blockade resistance and enables tumor regression

Dolina, J. S., Lee, J., Brightman, S. E., McArdle, S., Hall, S. M., Thota, R. R., Zavala, K. S., Lanka, M., Premlal, A. L. R., Greenbaum, J., et al. (2023) · Journal of Clinical Investigation · doi:10.1172/jci164258 · Cited by 68

An immunogenic personal neoantigen vaccine for patients with melanoma

Ott, P. A., Hu, Z., Keskin, D. B., Shukla, S. A., Sun, J., Bozym, D. J., Zhang, W., Luoma, A., Giobbie-Hurder, A., Peter, L., et al. (2017) · Nature · doi:10.1038/nature22991 · Cited by 2,936

Abstract CT022: IVAC® MUTANOME - A first-in-human phase I clinical trial targeting individual mutant neoantigens for the treatment of melanoma

Miller, M., Loquai, C., Kloke, B., Attig, S., Bidmon, N., Bolte, S., Bukur, V., Derhovanessian, E., Diekmann, J., Filbry, A., et al. (2016) · Cancer Research · doi:10.1158/1538-7445.am2016-ct022

Precision T-cell therapy targets tumours

Melief, C. J. M. (2017) · Nature · doi:10.1038/nature23093 · Cited by 28

Abstract PR02: A personalized neoantigen vaccine in patients with high risk melanoma

Ott, P. A., Hu, Z., Keskin, D. B., Shukla, S. A., Sun, J., Fritsch, E. F., Hacohen, N., & Wu, C. J. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.imm2016-pr02

Personalized melanoma vaccines

Kelly, P. N. (2017) · Science · doi:10.1126/science.357.6353.769-b